Seqirus

Tweet this page
<
2021
2022
>
No longer registered as of 02 May 2023 - Registration as it was on 13 May 2022
How to read and use this data card.
Download this datacard
The following entries are flagged as duplicates of this organisation: 359267936537-45

Overview

Lobbying Costs

400,000€ - 499,999€

Financial year: Jul 2020 - Jun 2021

Lobbyists (Full time equivalent)

1 Fte (1)

Lobbyists with EP accreditation

0

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    Seqirus

    EU Transparency Register

    205355142651-14 First registered on 06 May 2021

    Goals / Remit

    At Seqirus, we are driven by just one goal - to lessen the severity and impact of influenza, which can reach epidemic or even pandemic proportions with life-threatening consequences. Every year our influenza vaccines help protect millions of people. We find solutions to big, complex, challenging problems, and we see the results in the world around us. Then we do it all over again the following year. Seqirus is one of the largest influenza vaccine companies. We were created when our parent company, CSL Limited, acquired the Novartis influenza vaccine business and combined it with vaccine subsidiary, bioCSL.

    Main EU files targeted

    EU Health Data Space
    EU Health Emergency Response Authority
    EU Pharmaceutical legislation
    EU Emergency Authorisation Regulation
    ECDC and EMA

    Address

    Head Office
    Seqirus Level 3, 8AA, 29 Market St Maidenhead, Berkshire
    Maidenhead SL6 8AD
    UNITED KINGDOM
    EU Office
    Seqirus Level 3, 8AA, 29 Market St Maidenhead, Berkshire
    Maidenhead SL6 8AD
    UNITED KINGDOM

    Website

    http://seqirus.com

  • People

    Total lobbyists declared

    1

    Employment timeLobbyists
    100%1

    Lobbyists (Full time equivalent)

    1

    Lobbyists with EP accreditation

    No lobbyists with EP accreditations

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Companies & groups

  • Networking

    Affiliation

    Vaccines Europe
    European Federation of Pharmaceutical Associations (EFPIA)

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jul 2020 - Jun 2021

    Lobbying costs for closed financial year

    400,000€ - 499,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    NameAmount
    acumen public affars 100,000€ - 199,999€

    Intermediaries for current year

    Name
    acumen public affairs

    Closed year Costs

    400,000€ - 499,999€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    N/A

    Communication activities

    As members of the trade association Vaccines Europe, we have conducted an EU Flu Day campaign in 2020, 2021 and plan to do so again in 2022. We also hosted an event presenting research on public perceptions of flu post COVID pandemic in September 2021.

    Seqirus also makes grants to the European Scientific Working group on Influenza (ESWI) to support influenza scientific exchange and education and young scientist awards.

    Other activities

    None declared

  • Meetings

    Meetings

    None declared

Download this datacard